Sign In
Get Clay Free →

Suggestions

    Gerda M. Stetz, MBA

    Associate Director, Global Oncology Marketing

    Gerda M. Stetz, MBA is an Associate Director of Global Oncology Marketing specializing in Individualized Neoantigen Therapy at Merck.12 She is an award-winning pharmaceutical professional with expertise in launch planning, execution, brand building, creative development, and communication strategies.2

    Stetz has a long career at Merck, spanning various roles:

    • Associate Director, Global Oncology Marketing- Individualized Neoantigen Therapy (February 2024 - Present)
    • Associate Director, Global Marketing- Digital Content (September 2019 - February 2024)
    • Learning Consultant - Integrated Account Management (January 2017 - August 2019)
    • Executive Sales Representative (June 1997 - December 2016)
    • Professional Development Sales Trainer (August 2000 - January 2004)1

    Her educational background includes:

    • MBA from Rutgers University-New Brunswick (2004 - 2006)
    • Bachelor's degree from Villanova University (1993 - 1997)1

    Stetz has extensive experience in various aspects of the pharmaceutical industry, including brand development strategy, sales and marketing, customer relationship management, digital marketing, project management, and expertise in multiple therapeutic areas such as cardiology, endocrinology, diabetes, pulmonology, and oncology.1

    Recently, Stetz attended her first American Society of Clinical Oncology (ASCO) conference, where she expressed being inspired by the science, people, and patients to help bring innovative treatments to those fighting cancer.3

    Highlights

    Oct 28 · merck.com
    Merck and Moderna Initiate Phase 3 Trial Evaluating Adjuvant V940 ...
    Aug 28 · contactout.com
    Gerda Stetz Email & Phone Number | Associate Director, Global ...
    Jul 26 · merck.com
    Merck and Moderna Initiate Phase 3 Study Evaluating V940 (mRNA ...
    Jun 5 · modernatx.com
    Individualized Neoantigen Therapies - Moderna
    Apr 16 · merck.com
    Moderna and Merck Announce mRNA-4157 (V940), an ...
    Apr 13 · merck.com
    Individualized neoantigen therapies: exploring one medicine for one ...

    Related Questions

    What are Gerda M. Stetz's main responsibilities in her role at Merck?
    How has Gerda M. Stetz contributed to the development of individualized neoantigen therapies?
    What is Gerda M. Stetz's educational background?
    How long has Gerda M. Stetz been working at Merck?
    What are some notable projects Gerda M. Stetz has worked on at Merck?
    Gerda M. Stetz, MBA
    Gerda M. Stetz, MBA, photo 1
    Gerda M. Stetz, MBA, photo 2
    Add to my network

    Location

    United States